Publication News

An open-access research article led by Dr. Fazel Gorjipour, a NanoBio4Can MSCA Cofund Postdoctoral Programme Fellow at İzmir Biomedicine and Genome Centre, under the supervision of Prof. Dr. Şerif Şentürk, has been published in Results in Chemistry.

The research article titled “Spectral characterization and development of UV, direct fluorescence, and RP-HPLC-FLD assays for quantifying the BUB1 inhibitor BAY-1816032 in serum to support preclinical development” arose from Dr. Gorjipour’s NanoBio4Can project, which investigates targeted liposomal delivery of novel anticancer compounds for malignant pleural mesothelioma. Formulation development requires reliable measurement of drug loading, release, and partitioning in biological media. However, no simple, accessible method existed for BAY-1816032, and mass spectrometry can be costly and technically demanding.

After characterizing the compound’s UV absorption and fluorescence properties, the researchers developed three complementary approaches: UV absorption, direct fluorescence, and reverse-phase high-performance liquid chromatography with fluorescence detection (RP-HPLC-FLD). These methods establish an analytical foundation for liposome optimization, stability and serum-interaction studies, and future preclinical and pharmacokinetic evaluation.

Read the full article: https://www.sciencedirect.com/science/article/pii/S2211715626006673?via%3Dihub

This project has received funding from the European Union (EU), Horizon Europe Research and Innovation Programme under the Marie Skłodowska-Curie Actions (MSCA) – COFUND (Grant Agreement No. 101126492), and it is supported by the Scientific and Technological Research Council of Türkiye (TÜBİTAK) (Grant Agreement No. 123C460). Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or TÜBİTAK. Neither the European Union nor the granting authority can be held responsible for them.